AIM Vaccine Co., Ltd. (6660.HK)

7,020 -0,100 (-1,40%) Al cierre: 04:08PM HKT

AIM Vaccine Co., Ltd.

Tower A, Gemdale Plaza
Unit 2505-2507, 25th Floor 91 Jianguo Road Chaoyang District
Beijing
China

https://www.aimbio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 1624

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Yan Zhou	Executive Chairman & CEO	2,34M	N/A	1967
Mr. Xin Zhou	Executive Vice-Chairman of the Board	N/A	N/A	1970
Mr. Wen Guan	Vice-Chairman of the Board & Executive President	2,39M	N/A	1968
Mr. Shaojun Jia	COO, Executive President & Executive Director	2,62M	N/A	1964
Ms. Lixin Niu	Chief Financial Officer	N/A	N/A	1972
Ms. Ling Liu	Secretary & Chief Investment Officer	N/A	N/A	1984
Mr. Zhang Fan	Chief Research Officer	N/A	N/A	1987
Ms. Meng Li	Chief Quality Officer	N/A	N/A	1965
Ms. Zhou Wenjuan	Chief Public Affairs Officer	N/A	N/A	1979
Mr. Lin Zhenyu	Chief Marketing Officer	N/A	N/A	1975

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en HKD.

Descripción

AIM Vaccine Co., Ltd. researches, develops, manufactures, and commercializes of vaccine products for human use in the People's Republic of China. The company's product pipeline includes tetravalent meningococcal conjugate vaccine, that is in phase IV clinical trials indicated for meningococcal disease 13-Valent pneumonia Conjugate and 23-valent pneumonia Polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine which is in phase III clinical trials to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, that is in phase II trials for the treatment of meningococcal disease; EV71-CA16 Bivalent HFMD vaccine. In addition, the company develops 20-valent and 24-valent pneumonia conjugate vaccine, haemophilus influenzae type b conjugate vaccine, absorbed tetanus vaccine, quadrivalent influenza virus vaccine (MDCK Cells), and human diploid rabies vaccine. Further, it offers hexavalent meningococcal vaccine to treat meningococcal disease; hexavalent group b streptococcus polysaccharide conjugate vaccine; mRNA human rabies vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; diphtheria, tetanus and pertussis and haemophilus influenzae type b, and diphtheria, tetanus and acellular pertussis combination vaccine for the treatment of DTP; and recombinant group b meningococcal vaccine to treat meningococcal disease. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. The company was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

Gobierno corporativo

El ISS Governance QualityScore de AIM Vaccine Co., Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.